NCT03038438已完成不适用
A Multi-center, Non-randomized Study to Evaluate the Safety and Effectiveness of the Abre Venous Self-expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction
Medtronic Endovascular46 个研究点 分布在 6 个国家目标入组 260 人开始时间: 2017年12月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 260
- 试验地点
- 46
- 主要终点
- Primary Patency
研究概览
简要总结
Evaluate the safety and effectiveness of the Abre venous self-expanding stent system for treatment of symptomatic iliofemoral venous outflow obstruction in patients with venous occlusive disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 18 and ≤ 80 years of age;
- •Patient has at least one of the following clinical manifestations (i.e. symptoms and/or signs) of venous disease in lower extremity:
- •CEAP score ≥ 3
- •Venous Clinical Severity Score pain score (VCSS) ≥2
- •Suspected deep vein thrombosis (DVT);
- •Patient is willing and capable of complying with specified follow-up evaluations at the specified times;
- •Patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Ethics Board.
- •Patient has diagnosis of non-malignant venous obstruction within the common iliac, external iliac, and/or common femoral vein. The proximal point of the obstruction may extend to the iliac venous confluence of the inferior vena cava and the distal point may be at or above the deep femoral vein. Diagnosis must be made based on objective imaging by using venography and/or intravascular ultrasound (IVUS);
- •Patient has an obstructive lesion defined as:
- •Occluded, or
- •≥50% in diameter reduction on venography or IVUS, or
- •≥50% area reduction on IVUS
- •Acute DVT patients should be treated with the Abre stent within 14 days after onset of symptoms. Patients with acute DVT must first undergo successful treatment of acute thrombus by catheter based techniques; successful treatment is defined as 30% or less residual thrombus by venogram, as determined by physician, no bleeding, no symptomatic pulmonary embolism (confirmed by imaging), and no renal compromise (renal compromise defined as GFR>30). Patients with underlying obstructive lesions can then be included in the study within the same procedure;
- •Target vessel can accommodate a 9 French Sheath, from insertion site to target segment;
- •Exchangeable guidewire must cross target lesion(s) with successful predilation.
排除标准
- •Patient with DVT in the target limb of which the onset of symptoms is between 15 days and 6 months prior to planned treatment or patient has an acute DVT anywhere else than in the target vessel;
- •Patient has peripheral arterial disease causing symptoms in target limb;
- •Patient is pregnant, female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure;
- •Patient has a known or suspected systemic infection at the time of the index procedure;
- •Patient has a planned percutaneous or surgical intervention within 30 days prior or 30 days following index procedure, or a contralateral iliofemoral lesion requiring planned treatment within 12 months;
- •Patient requires femoral endovenectomy and patch venoplasty, greater saphenous vein ablation, and/or small saphenous vein stripping during the index procedure;
- •Patient has an active vasculitic inflammatory disorder (e.g. Behcet disease) predisposing the patient to thrombosis and requiring systemic corticosteroid therapy;
- •Patient has impaired renal function (GFR < 30) or is on dialysis;
- •Patient has a platelet count < 50,000 cells/mm3 or > 1,000,000 cells/mm3 and/or a White Blood Cell count < 3,000 cells/mm3 or > 12,500 cells/mm3;
- •Patient has a history of bleeding diathesis or either a history or presence of heparin induced thrombocytopenia antibodies;
- •Patient has a known hypersensitivity or contraindication to antiplatelets or anticoagulation, nitinol, or a contrast sensitivity that cannot be adequately pre-medicated;
- •Patient has presence of other severe co-morbid conditions, which in the investigator's opinion may interfere with the patient's compliance with study visits and procedures, or may confound interpretation of study data (e.g. congestive heart failure Class III and IV, non-ambulatory patients, severe hepatic dysfunction, life expectancy < 1 year);
- •Patient belongs to a vulnerable population per investigator's judgment or patient has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures. Patient must be able to consent for themselves;
- •Patient is currently participating in another investigational drug or device study or observational competitive study.
- •Patient has a vena cava obstruction or lesion extending into the inferior vena cava (IVC), or the presence of bilateral iliofemoral venous lesions requiring planned treatment within 12 months;
- •Patient has significant venous bleeding, arterial dissection or other injury requiring additional percutaneous or surgical intervention prior to enrollment;
- •Patient has a previously placed stent in the ipsilateral venous vasculature;
- •Patient has disease that precludes safe advancement of the venous stent to the target lesion(s)
结局指标
主要结局
Primary Patency
时间窗: 12 Months
Freedom from occlusion of the stented segment; Freedom from restenosis \>=50%; and Freedom from clinically-driven target lesion revascularization
Composite Major Adverse Events
时间窗: 30 Days
The components of the Major Adverse Events include: All-cause death occurring post-procedure, clinically-significant pulmonary embolism, major bleeding complication, stent thrombosis, and stent migration
次要结局
- Delayed Stent Migration(12 Months, 24 Months, 36 Months)
- Major Adverse Events(6 Months, 12 Months, 24 Months, 36 Months)
- Re-Hospitalization(0-180, 181-360, 361-720, 721-1080 and 0-1080 days)
- Villalta Score(Baseline to 6 Months, 12 Months, 24 Months, 36 Months)
- EuroQol-5 Dimension (EQ-5D) Score(Baseline to 6 Months, 12 Months, 24 Months, 36 Months)
- Device Success(Index Procedure)
- Lesion Success Obtained at Index Procedure(Index Procedure)
- Venous Clinical Severity Score (VCSS)(Baseline to 6 Months, 12 Months, 24 Months, 36 Months)
- Venous Insufficiency Epidemiological and Economic Study (VEINES) - Quality of Life/Symptoms (QOL/Sym) Score(Change from Baseline to 6 Months, 12 Months, 24 Months, 36 Months)
- Index Procedure Success(30 days)
- Primary Assisted Patency(12 Months, 24 Months, 36 Months)
- Secondary Patency(12 Months, 24 Months, 36 Months)
- Target Lesion Revascularization(30 days, 6 months, 12 months, 24 months, 36 months)
- Major Bleeding Related to Index Procedure(30 Days, 6 Months, 12 Months, 24 Months, 36 Months)
- Primary Patency(24 Months, 36 Months)
- Stent Fracture(30 Days, 12 Months, 24 Months, 36 Months)
研究者
研究点 (46)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac ArteriesIntermittent ClaudicationAtherosclerotic DiseaseThrombosisArterial Occlusive DiseaseNCT00352222Boston Scientific Corporation150
已完成
3 期
Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.Peripheral Vascular DiseaseNCT00844532Abbott Medical Devices151
进行中（未招募）
不适用
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm TreatmentIntracranial AneurysmNCT04999423Microvention-Terumo, Inc.206
已完成
不适用
Wingspan Stent System for Intracranial Artery StenosisIntracranial Artery StenosisStentEndovascular TherapyNCT06618222The First People's Hospital of Changzhou43
已完成
不适用
WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis StudyBiliary StrictureNCT01543256Boston Scientific Corporation172